What is Spatial Genomics?
Spatial Genomics operates at the intersection of advanced molecular biology and high-throughput data analytics. The company specializes in highly multiplexed spatial analysis, a transformative technology that allows researchers to simultaneously assay single-cell gene expression, protein expression, and genomic states within intact tissue samples. By mapping the complex architecture of cell neighborhoods and their functional interactions, the company provides critical insights that are essential for precision medicine, drug development, and diagnostic innovation. This capability to visualize the spatial context of biological processes represents a significant leap forward from traditional bulk sequencing methods, positioning Spatial Genomics as a key infrastructure provider for the next generation of life sciences research.
How much funding has Spatial Genomics raised?
Spatial Genomics has raised a total of $56M across 1 funding round:
Series A
$56M
Series A (2022): $56M with participation from 12 West Capital Management and Fulgent
Key Investors in Spatial Genomics
12 West Capital Management
An investment firm focused on long-term capital appreciation through strategic participation in high-growth technology and healthcare enterprises.
Fulgent
A premier, full-service genomic testing company that integrates advanced technology platforms to transform patient care in oncology, rare diseases, and reproductive health.
What's next for Spatial Genomics?
Looking ahead, the infusion of capital will likely be directed toward scaling the company's operational capacity and expanding its commercial footprint in the global diagnostics market. As the firm moves deeper into the enterprise-level funding stage, the focus will shift toward optimizing its technology platform for broader clinical adoption and fostering strategic partnerships within the pharmaceutical industry. By leveraging its unique ability to assess cell influences and interactions, Spatial Genomics is well-positioned to become a cornerstone of modern oncology and rare disease research. The company's roadmap suggests a continued emphasis on refining its assay throughput and data integration capabilities, ensuring that its spatial analysis tools remain at the forefront of the precision medicine revolution.
See full Spatial Genomics company page
